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Introduction 
The Stroke Recovery and Rehabilitation Roundtable (SRRR) meetings bring together an 
international group of preclinical and clinical researchers along with statisticians, 
methodologists, funders and consumers, to develop consensus-based core-recommendations 
for effective treatments for stroke recovery and to support best-evidence uptake in 
rehabilitation practice. We aim to complement, not replicate, the work of other 
collaborations. The breadth and ambition of stroke recovery and rehabilitation research 
requires synergistic collaborative work. The SRRR community is aligned in the search for 
life-changing recovery treatments, complementing what is currently available during the 
hyperacute phase. 
 
The first SRRR (SRRR I, 2016) was a major internati nal collaborative effort that set the 
scene for a new direction in recovery research. SRRR I focused on translation of preclinical 
evidence into human discovery trials (1); recovery biomarkers to provide knowledge of 
therapeutic targets and prognosis in human stroke (2); intervention development, monitoring, 
and reporting standards (3); and standardized measurement for motor recovery trials
 
(4). The 
impact of SRRR I continues to grow (see Figure 1).  
 
Leveraging momentum, SRRR II addressed targets identified at SRRR I as well as new areas 
for consensus (Figure 1, (5)). For example, while motor recovery was a logical target for 
early consensus building, the need for consensus around definitions, measurement and 
research priorities related to cognitive domains was evident (Theme 1, SRRR II). After 
establishing recommendations for core outcomes for motor recovery trials in SRRR I, 
improving our approach to measuring recovery and brain repair, not just functional change, 
was an important next step. This required recommendations for standardization of kinematics 
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to measure alterations in the quality of movement that accompanies motor system changes 
(Theme 2). In search for life-changing recovery treatments that are rigorously developed and 
tested, Theme 3 focused on how we build better recovery trials in the future. Theme 4 tackles 
the challenge of getting evidence-based treatments into practice (delivering what we know 
works). In this paper, we summarise the approach taken to build consensus, and the key 
outcomes of each theme including their consensus recommendations (6-9), which have been 
co-published in International Journal of Stroke and Neurorehabilitation and Neural Repair. 
 
< Please insert figure 1 here> 
 
Methods 
The SRRR II management group held monthly meetings from January 2018 until June 2019. 
All core working group members were invited by March 2018 and working groups 
subsequently established broader advisory groups. Each theme undertook a structured 
approach to consensus building and recommendation development. Part of this process 
included a face-to-face meeting of core participants (n=38) in Saint-Saveur, Canada in 
October 2018. A summary of the approach taken by each theme is presented in Table 1.  
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Table 1: Approach to consensus building for each Theme.  
Theme Approach to consensus building  
Cognitive impairment 
after stroke (9) 
 Development of a core working group with expertise in 
clinical stroke, non-human models of stroke, human and 
animal neuroimaging, neuropsychology, the neurobiology of 
language and cognitive rehabilitation.  
 Structured survey sent to core (n=9) and wider advisory group 
(n=6) members. From this, a list of major challenges was 
defined, and transformed into an agenda for the working 
group meeting. 
 Future directions for cognitive recovery research were 
mapped out. 
Standardized 
measurement of 
quality of upper limb 
movement after stroke 
(7) 
 Survey design and distribution to core (n=5) and advisory 
(n=8) group members 
 Analysis of the results of the survey  
 Face-to-face discussion  
 Draft recommendations developed and distributed to the core 
and advisory group for feedback   
Improving how we 
develop recovery 
trials (6) 
 Development of core working group members with expertise 
in clinical trials development and conduct, preclinical models 
of stroke, biomarkers, behavioural motor training and 
adjuvant therapies.  
 Consultation with core (n=12) and consultant (n=11) groups 
to identify ‘knowledge units’, which if addressed could 
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advance trial design. Information gathered through web-based 
survey and video-recorded meetings. 
 Prioritisation of evaluation criteria to make a judgment about 
importance of and confidence with available evidence to make 
GO, NO-GO decisions using graph theory-based voting 
system. 
 Conceptualisation of SRRR Trials Development Framework 
(SRRR-TDF). 
 Face-to-face application of SRRR-TDF to exemplar (upper 
limb recovery trial).  
 Development of exemplar, including collation of evidence, 
summary of issues and recommendations. 
Moving knowledge 
into practice (8) 
 Establish core working group (n=10) with international 
advisory group (n=18). 
 Review literature and develop criteria for prioritisation. 
 Survey health practitioners and people with stroke and their 
care-partners.  
 Consolidate categories of topics. 
 At face-to-face meeting to prioritise, vote to retain or exclude 
topics. Rank ordering not done. 
 Inductive approach to group topics into domains. 
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Theme 1: Cognitive impairment after stroke 
Previous international guidelines highlighted the lack of evidence on specific approaches for 
rehabilitation of cognitive function (10). Therefore, a major goal of the cognitive working 
group was to develop consensus on definitions and research priorities to identify major 
knowledge gaps, including alignment of preclinical and clinical research, in post-stroke 
cognition (9). 
 
The fact that cognition is multi-dimensional and hierarchical, creates difficulties for 
interventional research and building consensus around standardized assessment tools. As a 
consequence, the group decided that there was inadequate evidence to support formal 
consensus for trial methodology. However, there is an urgent need to define major priorities 
for research in post-stroke cognition to advance the field. There are a number of working 
groups engaged in defining cognitive impairments for vascular cognitive impairment (VCI) 
around the world. As such, this group focused primarily on the setting of stroke recovery and 
rehabilitation (process of care) trials. To build on our understanding of cognitive impairments 
and explore basic mechanisms of plasticity and repair, a bed-to-bench approach was adopted. 
This entails incorporating key aspects of human cognitive impairments (e.g., chronicity of 
impairment, executive dysfunction) and assessment in preclinical models. This is an 
important step in building a two-way interactive pipeline between preclinical and clinical 
research, which was viewed as central for cognitive recovery research and a core component 
of the working group’s mission. 
 
In order to move cognitive rehabilitation forward it is essential to understand how distributed 
neural networks, including interactions between remote regions, subserve different cognitive 
domains, (9, 11). Moreover, strokes that affect cognition frequently span multiple domains 
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resulting in complex cognitive impairments that can often occur weeks or months after 
stroke. Since cognitive impairments are a major determinant of quality of living (QoL) after 
stroke, our view is that assessment of cognitive function must meet predefined criteria for 
evaluation in all trials and observational studies of stroke recovery (see, McDonald et al., 
2019 Table 2). More longitudinal studies (both animal and human) with clinically relevant 
outcomes are needed to fully understand the evolution of post-stroke cognitive impairment 
and the associated mechanisms (e.g. brain connectivity changes) contributing to recovery. 
Such information is necessary to plan rational, biologically driven intervention trials. From 
such studies, sensitive cognitive biomarker readouts should be determined that can be 
implemented in Phase II and III trials.   
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Box 1: Cognitive consensus recommendations 
Observational studies and trials 
1. All clinical intervention studies and trials should include evaluation of cognition across 
multiple domains. 
2. Cognitive function should be evaluated at study enrolment and as an outcome measure 
(secondary if not primary). 
3. Wherever possible, studies should include evaluation of other behavioural aspects that 
are associated with cognition and important for quality of life: e.g. mood, apathy, 
fatigue, anxiety, sleep. 
4. Strategies to limit selection bias and selective attrition should be standard in clinical 
studies. Selection based on language deficits should require formal language 
assessment, and adjust test administration for aphasic patients when possible (eg using 
Supported Conversation (12)).  Reports should state who were excluded and why. 
5. Preclinical research should utilise models that reproduce common, clinically relevant 
cognitive deficits, using a battery of tests sensitive to multiple domains.  
 
Developmental priorities 
1. Measures of cognitive functioning better adapted to the needs of trials 
2. Parallel studies of cognitive functioning across multiple domains, with long follow up 
periods, in clinical and preclinical research to facilitate translation 
3. Identification of biomarkers for processes and epochs of recovery (identification of 
targets for intervention). 
4. Greater use of cognitive paradigms that translate between clinical and preclinical 
research (supported by standards for selection, execution and reporting of tests). 
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5. Preclinical models should incorporate age, sex, cardiovascular and metabolic 
comorbidities. 
 
 
Theme 2: Standardized measurement of quality of upper limb movement after stroke. 
Clinical trials and observational studies have failed to effectively explore the association 
between recovery of movement quality and upper limb capacity. Consequently, the 
distinction between behavioural restitution and compensation is poorly understood. There is 
therefore an urgent need to reach a consensus (13) on how to measure quality of movement in 
stroke recovery and rehabilitation trials to understand what patients learn and how they 
improve their upper limb capacity early post stroke. At the SRRR II consensus meeting, three 
key research questions were posed by the metric task force on the use of metrics for 
measuring the quality of movement: 1) Which performance assays of the paretic upper limb 
should be used to address questions about the quality of upper limb movement execution at 
the ICF level of body function? 2) Which functional task(s) should be recommended to 
measure quality of upper limb movement execution at the ICF level of activities? 3) Which 
types of technology (e.g., optoelectronic, electromagnetic movement tracking systems) 
should be recommended for measuring movement during performance assays and functional 
tasks? (7) At the impairment level, we recommended four performance assays (i.e., 2D planar 
standardized reaching movement, finger individuation, grip strength and precision grip). For 
the functional task we recommended using a standardized 3D-drinking task at activity level 
that addresses body function and activity respectively. We agreed that, given the current 
maturation of the technology and algorithms to generate metrics, only high speed and high-
resolution digital optoelectronic systems should be used to measure kinematics during the 
performance assays and the functional task. In contrast, wireless wearables including 2D and 
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3D-IMU’s, as well as Kinect or other optical systems are deemed currently inadequate for 
measuring the quality of movement.  
 
The consensus we achieved (Box 2) on measuring the quality of movement is imperative, to 
three aspects of understanding. Firstly, for stroke recovery and rehabilitation trials, and 
secondly to enable meaningful interpretation of neuroimaging studies (e.g. fMRI, DTI). 
Specifically, only by relating quality of movement and neural images is it possible to 
distinguish neural changes associated with behavioral restitution from compensatory 
strategies. This granularity of behavioral measurement is the only way that neuroimaging can 
make a useful contribution to neurorehabilitation (14, 15). Thirdly, standardization of 
kinematic measurement protocols will allow pooling of participant data, thereby increasing 
sample size aiding meta-analyses of published trials, more detailed exploration of recovery 
profiles, the generation of new research questions with testable hypotheses, and development 
of new treatment approaches focused on impairment. These consensus statements will serve 
as a blueprint for capturing recovery of the lower limb using kinetics and kinematic 
measures. 
 
Box 2: Measurement consensus recommendations 
1. By lack of current consensus, there is an urgent need to measure quality of movement 
in stroke recovery and rehabilitation trials to understand what patients learn and how 
they improve their upper limb capacity early post stroke.  
2. We recommend using the principles derived from motor control as a framework for 
measuring quality of movement.  
3. We recommend measuring the standardized 2D-reaching assay, finger individuation, 
pinch- and grip strength for assessment of assessment of behavioural restitution.  
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4. We recommend using the standardized 3D-reach-to-grasp drinking task for measuring 
recovery of upper limb capacity (see (7) for full details).  
5. The recommended 2D-reaching assays and 3D-drinking task should be measured 
repeatedly at fixed times post stroke concomitant with the recommended clinical 
measurements of outcome.  
6. We strongly recommend that only high-resolution digital optoelectronic systems be 
used to measure both performance assays and functional tasks. Only people who have 
the expertise and access to these technologies should therefore conduct quality of 
movement assessment.  
 
Theme 3: Improving how we develop recovery trials 
Stroke recovery treatments that set the field on a radical new path are critically needed (16). 
The SRRR II Next Trials working group (6) aimed to address the challenge of how we 
develop the next generation of stroke recovery trials to be both rigorous and aspirational to 
produce game-changing stroke reco ery treatments. We propose the SRRR-TDF to guide 
development of stroke recovery treatment trials, which incorporates recommendations from 
SRRR I (2-4, 16, 17) and decision analysis science. Stroke recovery trials in any treatment 
domain (speech and language, motor, cognition) require critical thinking and evidence 
gathering to appropriately inform decisions about whether to proceed with or hold off 
running a comparative effectiveness trial (i.e., the GO, NO-GO decision). This framework 
includes review of the evidence (preclinical and clinical), rating both the importance and 
confidence with available evidence to inform the start of the GO, NO-GO decision process. 
Where there is insufficient knowledge to proceed, research methods and earlier phase trial 
designs that can fill the knowledge gap need to be prioritised before proceeding to a Phase III 
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recovery trial. This framework complements existing guidelines for complex intervention 
development (18, 19).  
 
We use the term “knowledge units” to refer to important areas for consideration in trial 
development. From our process of consultation and prioritisation we identified five (5) 
knowledge units: HOW MUCH treatment, WHAT is an effective intervention (and the active 
ingredients), WHO to treat, and WHEN treatment is best delivered. These considerations 
apply to behavioural treatments, the current cornerstone of rehabilitation approaches. They 
also apply to ADJUVANT treatments, defined here as those treatments (e.g., drugs, non-
invasive brain stimulation) that aim to modify the effect of a primary behavioural 
intervention.  
 
We applied the SRRR-TDF to an exemplar trial (upper limb recovery). The core working 
group drew on systematic reviews, preclinical experiments and clinical trials in our evidence 
summaries. It was not our intention to conduct a rigorous systematic review of primary 
literature for each knowledge unit; although doing so would be justified in a real-world 
scenario. We found that the evidence for most knowledge units is currently inadequate to 
support a late phase upper limb recovery trial. This indicates that additional, earlier phase 
trials are needed to address priority gaps. From this work, we developed eight 
recommendations (Box 3).  
 
In summary, rigorous appraisal of the evidence that underpins essential knowledge units is 
needed in developing a trial will ultimately lead to fewer, but better, trials progressing to 
Phase III.  
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Box 3: Next trials consensus recommendations 
1. Researchers interested in developing comparative effectiveness recovery trials in any 
domain (speech and language, motor, cognition etc) should apply the SRRR-TDF when 
developing trials, ensuring that all ‘knowledge units’ have been considered in the 
process to inform GO, NO-GO decisions. 
2. When there is insufficient evidence to support a decision (i.e., NO-GO), the researcher 
should proceed to fill this knowledge gap. This may prompt an earlier phase design(s), 
potentially followed by a feasibility study to inform the trial that will answer the 
primary question, i.e., does the intervention work?  
3. Funders of stroke research need to support earlier phase programs of research that aim 
to develop evidence to inform critical knowledge units in stroke recovery. These 
programs should be prioritised above large Phase III trials that do not have sufficiently 
strong biological evidence of effect or have positive findings from a single pilot trial. If 
progress is warranted, recommendations for intervention detailing, monitoring and 
reporting from the SRRR I should be followed (3). 
4. HOW MUCH: To report dose, future trials should report all elements of dose 
(including repetitions, duration, intensity) and dose schedule, from all arms of the trial. 
Threshold d ses for effectiveness need to be determined (20-22). 
5. WHAT: Effective training is likely to comprise several elements. Studies that aim to 
optimise promising treatments and use fine grained behavioural outcomes are required. 
These may identify active ingredients for further testing.  
6. WHO: Hypothesis-driven studies to identify reliable and valid assessments that 
distinguish biological subgroups, and responses to treatment are needed across both 
preclinical and clinical. Current potential stratification approaches need further testing 
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in trials. 
7. WHEN: Complete clinical trials that enrol patients based on days post stroke, in epochs 
that are time-linked to our current understanding of the neurobiology of recovery. 
Greater focus on enrolling patients earlier post stroke is needed given the strength of 
preclinical evidence.  
8. ADJUVANTS: Clinical and preclinical researchers should jointly design studies to 
systematically test if training combined with an adjuvant is better than training alone. 
Careful phasing and reporting of trials is needed.   
 
 
Theme 4: Moving knowledge into practice 
The Knowledge Translation group of SRRR II (8) brought together experts with an 
international perspective to gain consensus about priorities for implementing practice change 
in the area of stroke rehabilitation. Firstly, the group determined the criteria on which the 
prioritization process would be based on from the literature and consensus. This forms the 
first recommendation of the group; health system managers looking to implement new 
practices should choose practices with a high level of research evidence that provide 
meaningful impact to stroke survivors and are feasible while considering how this will 
influence the delivery of services in the local health system context. These criteria are 
transferable to other clinical areas and may be used by other researchers.   
 
Input from health care providers (n=502) and patients (and their families) (n=112) from over 
28 countries informed the recommendations (Box 4) as they are the ultimate end-users as 
those delivering the treatment and those receiving the treatment.  Several areas that were 
deemed high priority for practice change can be addressed by redesigning health services 
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with minimal new costs. For example, improving communication processes for providing 
patient centred services or interdisciplinary care was identified to improve the coordination of 
services. Increasing the intensity of physical rehabilitation was identified across multiple 
professions (nurses, physical therapists, occupational therapists and speech language 
pathologists) to improve patient outcomes. Screening and assessment for dysphagia, 
depression and cognition was prioritized because these have well-established protocols that 
are not consistently adopted into practice. Increasing the use of established clinical practice 
guidelines and upskilling of staff were also priorities. Both health care providers and people 
with stroke identified family support and caregiver training as well as self-management 
strategies as high priority to implement. In particular, social isolation was a frequent concern 
from consumers, and healthcare providers should be aware of how to assess social isolation 
and implement social support interventions. Of note, the topic of fatigue was frequently 
raised by consumers but was not included as an implementation priority, but rather a topic 
requiring more primary research.   
 
A number of system level changes were prioritized in this consensus process which could 
improve quality of life as well as service efficiencies. Health system managers should 
prioritize changes that support early access to services and transitions in care, especially back 
to the community. While it is recognized that health care shortfalls may impact the ability to 
provide new resources, two areas were identified to provide the most impact. Increasing staff 
numbers and especially staff who have expertise in managing people with stroke, as well as 
access to technology were identified as resources that were essential to enhance 
rehabilitation.   
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While interventions with a strong evidence base were prioritized, research is still required to 
determine the best ways to change practice in different contexts.  Therefore, funders have an 
important role to play in supporting this knowledge translation research. Funding agencies 
can use recommendations provided to prioritize funding for maximum impact. 
 
Box 4: Moving knowledge into practice consensus recommendations 
1. When identifying treatments to move to stroke rehabilitation practice consider the 
research evidence, personal impact, feasibility and system impact. 
2. Interventions that are ready to be implemented include those which improve 
interdisciplinary care, screening (i.e., for dysphagia, depression and cognition), 
intensity of rehabilitation and support for families and caregivers. The use of clinical 
guidelines and education can support these initiatives. 
3. System level changes should prioritize early access to rehabilitation and support 
transitions in care, especially into the community.   
4. Health care funding should be directed to increasing the number of staff, especially 
those with stroke specific expertise, and improving access to technology.  Knowledge 
translation research funding is needed to determine the best ways to improve uptake of 
research evidence into clinical practice in stroke rehabilitation.   
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Conclusion 
The Stroke Recovery and Rehabilitation Roundtables have served to unite people who are 
committed to progressing stroke recovery and rehabilitation science and practice, and 
interested in building strong, international partnerships to accelerate change. We hope that 
researchers, clinicians and academics in the field of stroke recovery, together with funding 
bodies and journal editors, will join us in pursuing and promoting the goals outlined here (6-
9) and in our previous recommendation papers (1-4, 16), and support our vision for change. 
We believe the next step is to grow a broader international alliance of clinicians, researchers, 
consumers and other stakeholders from across the world, who can work together to action 
these and other recommendations. Collective action will serve to accelerate progress in this 
exciting, but relatively neglected field. As a group, we remain optimistic that alignment of 
our efforts will yield important discoveries, and better implementation of effective treatments 
that will ensure people affected by stroke achieve optimal recovery and quality of life. We 
invite interested parties to join us. 
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Figure 1: Development of Stroke Recovery and Rehabilitation Roundtables (SRRR I and II), 
and International Stroke Recovery and Rehabilitation Alliance (ISRRA). Reproduced with 
permission, Bernhardt et al., 2019 International Journal of Stroke;14:450-456. 
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